See more : United Spirits Limited (MCDOWELL-N.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Pliant Therapeutics, Inc. (PLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pliant Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bounce Mobile Systems, Inc. (BNCM) Income Statement Analysis – Financial Results
- CTT – Correios De Portugal, S.A. (CTTPY) Income Statement Analysis – Financial Results
- Roche Holding AG (ROG.SW) Income Statement Analysis – Financial Results
- Datasea Inc. (DTSS) Income Statement Analysis – Financial Results
- Macpower CNC Machines Limited (MACPOWER.NS) Income Statement Analysis – Financial Results
Pliant Therapeutics, Inc. (PLRX)
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.58M | 9.69M | 7.57M | 41.82M | 57.05M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 3.68M | 3.20M | 0.00 | 0.00 | 666.00K | 0.00 |
| Gross Profit | 1.58M | 6.00M | 4.37M | 41.82M | 57.05M | -666.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 61.99% | 57.69% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 127.80M | 96.94M | 77.55M | 66.19M | 47.35M | 24.42M | 14.53M |
| General & Administrative | 57.93M | 39.95M | 27.56M | 17.27M | 10.93M | 6.50M | 3.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.93M | 39.95M | 27.56M | 17.27M | 10.93M | 6.50M | 3.82M |
| Other Expenses | 0.00 | 0.00 | -77.55M | -366.00K | -216.00K | -49.00K | 0.00 |
| Operating Expenses | 185.73M | 136.89M | 27.56M | 83.46M | 58.28M | 30.92M | 18.35M |
| Cost & Expenses | 185.73M | 136.89M | 27.56M | 83.46M | 58.28M | 30.92M | 18.35M |
| Interest Income | 24.08M | 4.67M | 272.00K | 478.00K | 816.00K | 688.00K | 16.00K |
| Interest Expense | 1.27M | 791.00K | 272.00K | 366.00K | 216.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.84M | 3.68M | 3.20M | 1.31M | 1.11M | 666.00K | 292.00K |
| EBITDA | -158.23M | -118.85M | -95.73M | -40.34M | -118.00K | -30.25M | -18.06M |
| EBITDA Ratio | -10,014.43% | -1,265.15% | -263.95% | -99.59% | -0.21% | 0.00% | 0.00% |
| Operating Income | -184.15M | -127.20M | -19.99M | -41.65M | -1.23M | -30.92M | -18.35M |
| Operating Income Ratio | -11,654.75% | -1,313.37% | -263.95% | -99.59% | -2.16% | 0.00% | 0.00% |
| Total Other Income/Expenses | 22.81M | 3.88M | 272.00K | 112.00K | 600.00K | 639.00K | 16.00K |
| Income Before Tax | -161.34M | -123.32M | -19.71M | -41.53M | -631.00K | -30.28M | -18.33M |
| Income Before Tax Ratio | -10,211.14% | -1,273.32% | -260.35% | -99.32% | -1.11% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.82M | -1.81M | -1.79M | -816.00K | 639.00K | 2.29M |
| Net Income | -161.34M | -121.50M | -17.91M | -39.75M | 185.00K | -30.28M | -20.62M |
| Net Income Ratio | -10,211.14% | -1,254.50% | -236.49% | -95.05% | 0.32% | 0.00% | 0.00% |
| EPS | -2.75 | -2.89 | -0.50 | -1.12 | 0.01 | -1.83 | -25.67 |
| EPS Diluted | -2.75 | -2.89 | -0.50 | -1.12 | 0.01 | -1.83 | -25.67 |
| Weighted Avg Shares Out | 58.72M | 42.02M | 35.85M | 35.55M | 35.55M | 16.51M | 803.50K |
| Weighted Avg Shares Out (Dil) | 58.72M | 42.02M | 35.85M | 35.55M | 35.55M | 16.51M | 803.50K |
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
Source: https://incomestatements.info
Category: Stock Reports